Dr. Noureddin is the current Director of the Houston Liver Institute and former founding Director of the Fatty Liver Program at Cedars-Sinai. He completed his residency at the University of Southern California and completed a hepatology fellowship at the NIH and gastroenterology fellowship at University of California San Diego.

Dr. Noureddin has led efforts in several breakthrough clinical trials targeting new therapies in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those with advanced fibrosis and cirrhosis. He also focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver transplant, liver cancer, new imaging modalities, and exploring new treatments.

Dr. Noureddin has conducted more than 40 investigational clinical studies of novel treatments for non-alcoholic steatohepatitis (NASH). Dr. Noureddin has published 180 papers in the field of NASH in many journals including: The Lancet, Lancet Gastroenterology & Hepatology, Science Trinational Medicine, Gastroenterology, Journal of Hepatology, Journal of Clinical Investigation, Hepatology, Clinical Gastroenterology and Hepatology and others.

Dr. Lake is Associate Professor of Medicine with Tenure at UTHealth McGovern Medical School. She completed both medical school and Internal Medicine residency at Baylor College of Medicine in Houston, Texas, followed by an Infectious Diseases fellowship and Master of Science in Clinical Research degree program at the University of California, Los Angeles. Dr. Lake’s outpatient practice focuses on adults living with HIV, and gender care for transgender women with HIV.  Her translational research portfolio focuses on the treatment of metabolic complications of HIV and antiretroviral therapy, with particular expertise in translational clinical trials. Dr. Lake also serves leadership positions in the NIH-funded MACS/WIHS Combined Cohort Study and AIDS Clinical Trials Group.

Dr. Hope Rugo is the Director of the Breast Oncology Clinical Trials Program at UCSF.  She is the principal investigator for multiple clinical trials studying novel targeted therapeutics combined with standard treatments to improve clinical results in early and late-stage breast cancer.  She is also researching cognitive function in patients receiving chemotherapy for breast cancer as well as ways to reduce toxicity from therapy.

Dr. Rugo has established collaborations with several large academic medical centers to expand the novel therapies that are available to patients. She is an active member of the national cooperative group, CALGB, a founding member of the Breast Cancer Research Consortium, and an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer).

Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally, and internationally. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families, and friends from throughout the Bay Area.  She is widely published and highly regarded in the field of oncology.

Dr. Ueno is a Professor of Medicine at The University of Texas MD Anderson Cancer Center. He is the Executive Director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic and Section Chief of the Translational Breast Cancer Research at the Department of Breast Medical Oncology. His research is in the area of inflammatory breast cancer/triple-negative breast cancer. In particular, he focuses on the molecular mechanism of metastasis and tumorigenicity driven by cancer microenvironment. 

Dr. Ueno is best known for his preclinical/clinical development for E1A, EGFR, HER2, MAPK pathway targeting therapy leading to novel clinical trials. His research determined the immune response that predicts sensitivity to anti-epidermal growth factor receptor (EGFR) therapy for inflammatory breast cancer (IBC) and developed novel treatment strategies by modulating the IBC microenvironment. He has conducted numerous phase 1/2 clinical trials of targeted therapy in patients with aggressive breast cancer.

Dr. Kabir Mody is the Medical Director at IMV, Inc. and a board-certified medical oncologist. He brings a wealth of experience and knowledge in oncology and immuno-oncology accumulated while working at Mayo Clinic as an academic oncologist focused on GI oncology, in particular cancers of the liver and the pancreas. Dr. Mody received his MD from St. George's University School of Medicine, completed his residency at St. Luke’s-Roosevelt Hospital in New York City and fellowship at Dartmouth Hitchcock Medical Center in New Hampshire. He has co-authored numerous papers and book chapters, including many on the biology and novel treatment strategies of liver and pancreas malignancies, and has been actively involved in leading both clinical and lab-based research on cancers of the liver and pancreas. 

Dr. Eric Mininberg is a board-certified medical oncologist at Piedmont Cancer Institute and a Diplomat of the American Board of Internal Medicine.  He graduated from Dartmouth College in 1993 with a degree in government and obtained a medical degree from the University of Virginia School of Medicine. He completed his residency at the University of Virginia Medical Center. He was a Hematology fellow at Baylor University and a Medical Oncology fellow at the University of Texas MD Anderson Cancer Center.

Dr. Mininberg is the recipient of numerous honors and awards. He was inducted in 1989 as a member of Cum Laude Society with St. Albans School in Washington, DC. While at The University of Texas MD Anderson Cancer Center, he was honored with the Elsa U. Pardee Foundation Grant for Community Oncology. As a fellow in 2003 he was awarded the American Society of Clinical Oncology Merit Award. He holds memberships with the Dartmouth and University of Virginia Alumni Associations, as well as the American and Georgia Societies of Clinical Oncology.

He has numerous publications and abstracts in Hematology and Oncology. 

Dr. Mininberg will specifically support CytoDyn’s clinical trial enrollment in the southeast region and further exploration of leronlimab PRO 140’s indications in oncology.

Dr. Sacha graduated cum laude from the University of Missouri-Columbia in 2003 with a B.A. in German and B.S. in Biology.  After receiving his Ph.D. in Medical Microbiology & Immunology from the University of Wisconsin-Madison in 2007, he joined the faculty at UW-Madison, where he researched the characteristics of effective retrovirus-specific CD8+ and CD4+ T cells.  In 2011, he joined the Oregon Health & Science University and has appointments in both the Vaccine & Gene Therapy Institute and Oregon National Primate Research Center.

Dr. Sacha will lead CytoDyn’s team efforts in HIV PreP and HIV cure.

Dr. Otto Yang is a Professor of Medicine, Infectious Diseases, Microbiology, Immunology & Molecular Genetics at UCLA and has a background in clinical infectious diseases. His laboratory specializes in T cell immunology in HIV infection, relevant to developing immune therapies and vaccines for HIV and potentially other diseases including cancer and other viral infections. He received his MD degree from Brown University, with subsequent residency training at NYU-Bellevue Hospital and subspecialty/postdoctoral training at Harvard-Massachusetts General Hospital. He then pursued fellowship at Massachusetts General Hospital, where he developed a research program studying the role of CD8+ T lymphocytes (CTL, which are killer T cells that can destroy cells infected with viruses or which are malignant) in HIV-1 pathogenesis. A more recent research interest has been the role of CTL in the development of rejection in organ transplant patients. Dr. Yang has begun working with the new composite tissue transplantation program at UCLA, which will perform hand and face transplants, studying the role of this arm of immunity in causing tissue rejection. Dr. Yang is a frequent lecturer, received numerous research grants and funding for his work, published over 180 peer-reviewed articles, and holds numerous patents in HIV and Immunology.

Appointed to CEO in January 2024, Dr. Lalezari brings over 34 years of industry experience to the Company, including nearly 20 years of experience with leronlimab, also known as PRO 140. He previously served as interim CEO of CytoDyn from November 2023 to January 2024, Chief Medical Officer during 2020, and has been a member of the Company’s scientific advisory board for the past several years.  Dr. Lalezari has been the CEO and Medical Director of Quest Clinical Research since 1996, and served as the Chief Medical Officer of Virion Therapeutics in 2018. Dr. Lalezari has served as Principal Investigator for Phase I, II, and III clinical studies of new therapies for such viral diseases as HIV/AIDS, CMV, HPV, HSV, Hepatitis B and C, influenza, RSV, and COVID-19, including clinical trials conducted by the Company. His work has been published extensively and he is a well-regarded international speaker and patient advocate. Dr. Lalezari received his M.D. from the University of Pennsylvania, his M.A. from the University of Virginia, and his B.A. from the University of Rochester. He also holds a board certification from the American Board of Internal Medicine.